Risks for AERIE PHARMACEUTICALS INC (AERI)

Here are some interesting risks from the recent filings of AERIE PHARMACEUTICALS INC. Our algorithms work hard to highlight risks unique to this company.

We operate in an industry that involves numerous risks and uncertainties. The risks and uncertainties described below are not the only ones we face. Other risks and uncertainties, including those that we do not currently consider material, may impair our business. If any of the risks discussed below actually occur, our business, financial condition, operating results or cash flows could be materially adversely affected. This could cause the trading price of our common stock to decline.

We depend substantially on the success of our FDA-approved product Rhopressa

, if approved, or experience significant delays in doing so, our business will be materially harmed.

and any future product candidates, if approved, will depend on the degree of market acceptance among eye-care professionals, patients, patient advocacy groups, healthcare payers and the medical community.

If we fail to obtain and sustain an adequate level of coverage and reimbursement for Rhopressa